Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$92.79M, compared with -$69.41M a year earlier.
Context
- Retained earnings amounted to 883.3% of total assets at the end of Q1 FY2026, down 1640.0 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -33.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (87.14M) USD
- Year-over-year change
- -31.7%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (87.14M) | -31.7% |
| FY2024 | 2024-12-31 | (66.15M) | -31.3% |
| FY2023 | 2023-12-31 | (50.36M) | -21.4% |
| FY2022 | 2022-12-31 | (41.47M) | -23.3% |
| FY2021 | 2021-12-31 | (33.65M) | — |
Retained Earnings vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -33.7% is the 6th highest of 9, against a peer median of -21.7%.
- Retained earnings amounts to 883.3% of total assets for GLSI, versus a peer median of 521.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$92.79M USD | -33.7% | — | 883.3% | |
| Mar 2026 | -$114.55M USD | -44.0% | — | 119.6% | |
| Mar 2026 | -$148.72M USD | -26.3% | — | 500.7% | |
| Mar 2026 | -$203.22M USD | -10.7% | — | 562.3% | |
IRDOpus Genetics, Inc. | Mar 2026 | -$254.12M USD | -72.6% | — | 380.5% |
| Mar 2026 | -CA$438.74M CAD | +9.4% | — | 5376.0% | |
| Mar 2026 | -$482.81M USD | -17.1% | — | 177.4% | |
| Mar 2026 | -$654.79M USD | -109.7% | — | 542.5% | |
| Mar 2026 | -$2.14B USD | +2.9% | — | 1149.6% | |
| Peer median (excluding GLSI) | — | -21.7% | — | 521.6% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.